$ACRS News

Aclaris Therapeutics, Inc. (ACRS) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Aclaris Therapeutics Q1 EPS $(0.15), Inline, Sales $1.996M Beat $1.322M Estimate

Piper Sandler Maintains Overweight on Aclaris Therapeutics, Raises Price Target to $11

Guggenheim Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $12

Wedbush Maintains Outperform on Aclaris Therapeutics, Raises Price Target to $10

Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates - Slideshow

Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript

Aclaris Therapeutics Announces Top Line Results From Its Phase 1a Single And Multiple Ascending Dose Trial Of Its Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 And The Selection Of Lichen Llanus As The lead Indication For Its Selective ITK/JAK3 Inhibitor ATI-2138

Aclaris Therapeutics to Reveal Clinical Update On Key Biologic And Oral Inhibitor Programs on April 28, 2026

Oppenheimer Initiates Coverage On Aclaris Therapeutics with Outperform Rating, Announces Price Target of $10

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Wedbush Reiterates Outperform on Aclaris Therapeutics, Maintains $8 Price Target

Results Presented at 2026 American Academy of Dermatology (AAD) Annual Meeting Provide Additional Support for the Therapeutic Potential of ATI-2138

Aclaris Therapeutics Presents Additional Results From Phase 2a Trial Of ATI-2138, Potent And Selective Investigational Oral Covalent Inhibitor Of ITK And JAK3, At 2026 AAD Annual Meeting

Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains?

Aclaris Therapeutics Announces Poster on Results from Phase 2a Trial of ATI-2138 at the 2026 American Academy of Dermatology (AAD) Annual Meeting

Aclaris Therapeutics To Present Results From Open-Label Phase 2a Trial Of ATI-2138, Investigational Oral Covalent Inhibitor Of Interleukin-2-ITK And JAK3, At 2026 AAD Annual Meeting

HC Wainwright & Co. Reiterates Buy on Aclaris Therapeutics, Maintains $16 Price Target

Aclaris Therapeutics Completes Enrollment in Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

Aclaris Therapeutics Completes Enrollment Of 109 Patients In Phase 2 Trial Of Bosakitug For Moderate-To-Severe Atopic Dermatitis, Top Line Results Due Q4 2026